Antiproliferative effect of somatostatin analogs in advanced gastro-entero-pancreatic neuroendocrine tumors: a systematic review and meta-analysis

Elettra Merola, Francesco Panzuto and Gianfranco Delle Fave _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:46624-46634. https://doi.org/10.18632/oncotarget.16686

Metrics: PDF 1736 views  |   HTML 2284 views  |   ?  


Elettra Merola1, Francesco Panzuto1 and Gianfranco Delle Fave1

1 Department of Digestive and Liver Diseases, Sapienza University, Sant’Andrea Hospital, Rome, Italy

Correspondence to:

Gianfranco Delle Fave, email:

Keywords: gastro-entero-pancreatic neuroendocrine tumors, somatostatin analogs, antiproliferative effect, meta-analysis

Received: January 20, 2017 Accepted: March 17, 2017 Published: March 29, 2017


A meta-analysis has systematically investigated the antineoplastic efficacy and safety of somatostatin analogs (SSAs) in advanced gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs). Randomized controlled trials (RCTs) reporting the hazard ratio (HR) for disease progression (DP) were evaluated. Response rate and risk ratio (RR) for adverse events were also analyzed. A total of 289 patients (143 receiving SSAs vs. 146 placebo) were evaluated from two RCTs. A significant benefit from SSAs in terms of disease control was observed (HR 0.41, 95% CI: 0.29 to 0.58, P < 0.01; I20%), response rate being 58.0% vs. 32.2%, respectively.The occurrence of adverse events significantly differed from the placebo arm only in terms of biliary stones (RR 3.79, 95% CI: 1.28 to 11.17, P = 0.02; I20%). In conclusion, SSAs showed an antiproliferative effect in advanced GEP-NETs, with a good safety profile.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 16686